Michel M Tod

Ontology type: schema:Person     

Person Info


Michel M



Publications in SciGraph latest 50 shown

  • 2022-06-23 Quantitative Prediction of Adverse Event Probability Due to Pharmacokinetic Interactions in DRUG SAFETY
  • 2022-03-31 Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era in BRITISH JOURNAL OF CANCER
  • 2022-02-15 Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 2021-03-17 Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study in THE PHARMACOGENOMICS JOURNAL
  • 2021-03-08 Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates in PHARMACEUTICAL RESEARCH
  • 2020-08-10 Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? in CLINICAL DRUG INVESTIGATION
  • 2020-06-12 Azithromycin for COVID-19: More Than Just an Antimicrobial? in CLINICAL DRUG INVESTIGATION
  • 2020-06-04 Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2020-05-25 Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation in INVESTIGATIONAL NEW DRUGS
  • 2019-12-20 Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal Cells in THE AAPS JOURNAL
  • 2019-12-16 Quantitative Prediction of Interactions Mediated by Transporters and Cytochromes: Application to Organic Anion Transporting Polypeptides, Breast Cancer Resistance Protein and Cytochrome 2C8 in CLINICAL PHARMACOKINETICS
  • 2018-09-08 A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4 in CLINICAL PHARMACOKINETICS
  • 2018-06-15 Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-03-23 Identification of Cytochrome P450-Mediated Drug–Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model in CLINICAL PHARMACOKINETICS
  • 2017-09-09 Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism in CLINICAL PHARMACOKINETICS
  • 2017-08-17 Population Pharmacokinetics of Stiripentol in Paediatric Patients with Dravet Syndrome Treated with Stiripentol, Valproate and Clobazam Combination Therapy in CLINICAL PHARMACOKINETICS
  • 2017-03-09 Respiratory depression related to multiple drug–drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2016-12-06 A Model for Predicting the Interindividual Variability of Drug-Drug Interactions in THE AAPS JOURNAL
  • 2016-06-21 Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: Handling Sacrifice Censoring and Error Caused by Experimental Measurement on Larger Tumor Sizes in THE AAPS JOURNAL
  • 2016-03-02 Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers in CLINICAL PHARMACOKINETICS
  • 2016-01-12 Improvement of Parameter Estimations in Tumor Growth Inhibition Models on Xenografted Animals: a Novel Method to Handle the Interval Censoring Caused by Measurement of Smaller Tumors in THE AAPS JOURNAL
  • 2015-09-21 Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-07-04 Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods in BMC RESEARCH NOTES
  • 2015-06-13 A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child–Pugh Classification in CLINICAL PHARMACOKINETICS
  • 2015-01-06 Quantitative Methods for Prediction of the Effect of Cytochrome P450 Gene Polymorphisms on Substrate Drug Exposure in CLINICAL PHARMACOKINETICS
  • 2014-12-12 Pharmacokinetics of Clobazam and N-Desmethylclobazam in Children with Dravet Syndrome Receiving Concomitant Stiripentol and Valproic Acid in CLINICAL PHARMACOKINETICS
  • 2014-10-25 Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients in INVESTIGATIONAL NEW DRUGS
  • 2014-10-02 Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data in THE AAPS JOURNAL
  • 2014-06-06 Prédiction de la résistance à la chimiothérapie des tumeurs trophoblastiques gestationnelles (TTG) de bas risque par l’analyse de la cinétique des hCG in ONCOLOGIE
  • 2014-05-27 Consequences of Renal Failure on Non-Renal Clearance of Drugs in CLINICAL PHARMACOKINETICS
  • 2014-02-20 Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients in BRITISH JOURNAL OF CANCER
  • 2014-02-14 Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach in THE AAPS JOURNAL
  • 2013-11-20 Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-09-12 Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach in THE AAPS JOURNAL
  • 2013-04-16 Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements in BRITISH JOURNAL OF CANCER
  • 2013-01-24 Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure in CLINICAL PHARMACOKINETICS
  • 2013-01-15 In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates in THE AAPS JOURNAL
  • 2012-10-17 Pharmacodynamic Models for Discrete Data in CLINICAL PHARMACOKINETICS
  • 2012-07-05 Sorafenib in advanced melanoma: a critical role for pharmacokinetics? in BRITISH JOURNAL OF CANCER
  • 2012-01 A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy in CLINICAL PHARMACOKINETICS
  • 2011-10-18 Saturable absorption of sorafenib in patients with solid tumors: a population model in INVESTIGATIONAL NEW DRUGS
  • 2011-08-24 Genotype‐Based Quantitative Prediction of Drug Exposure for Drugs Metabolized by CYP2D6 in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2011-08-02 Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-08 Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions in CLINICAL PHARMACOKINETICS
  • 2011-06-21 Functional and Clinical Evidence of the Influence of Sorafenib Binding to Albumin on Sorafenib Disposition in Adult Cancer Patients in PHARMACEUTICAL RESEARCH
  • 2011-05-28 Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen in ORPHANET JOURNAL OF RARE DISEASES
  • 2011-03-19 Closed Abdomen Hyperthermic Intraperitoneal Chemotherapy with Irinotecan and Mitomycin C: a Phase I Study in ANNALS OF SURGICAL ONCOLOGY
  • 2010-11-04 Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4 in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 2010-10-21 Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model in PHARMACEUTICAL RESEARCH
  • 2010-09-02 Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model in PHARMACEUTICAL RESEARCH
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.7849.2", 
              "type": "Organization"
            "isCurrent": true, 
            "type": "OrganizationRole"
            "id": "http://www.grid.ac/institutes/grid.411119.d", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.413306.3", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.412134.1", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.7429.8", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.411784.f", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.414106.6", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.413784.d", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.411430.3", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.25697.3f", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.411388.7", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.413852.9", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.9621.c", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.424469.9", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.417713.7", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.413780.9", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.418116.b", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.50550.35", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.11318.3a", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.508487.6", 
            "type": "Organization"
            "id": "http://www.grid.ac/institutes/grid.462854.9", 
            "type": "Organization"
        "familyName": "Tod", 
        "givenName": "Michel M", 
        "id": "sg:person.0763711421.46", 
        "sameAs": [
        "sdDataset": "persons", 
        "sdDatePublished": "2022-12-01T07:12", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/person/person_670.jsonl", 
        "type": "Person"

    Download the RDF metadata as:  json-ld nt turtle xml License info


    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0763711421.46'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0763711421.46'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0763711421.46'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0763711421.46'


    This table displays all metadata directly associated to this object as RDF triples.

    56 TRIPLES      10 PREDICATES      31 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.0763711421.46 schema:affiliation N9bad6795a44d4d8faff52f902fe94e09
    2 grid-institutes:grid.11318.3a
    3 grid-institutes:grid.25697.3f
    4 grid-institutes:grid.411119.d
    5 grid-institutes:grid.411388.7
    6 grid-institutes:grid.411430.3
    7 grid-institutes:grid.411784.f
    8 grid-institutes:grid.412134.1
    9 grid-institutes:grid.413306.3
    10 grid-institutes:grid.413780.9
    11 grid-institutes:grid.413784.d
    12 grid-institutes:grid.413852.9
    13 grid-institutes:grid.414106.6
    14 grid-institutes:grid.417713.7
    15 grid-institutes:grid.418116.b
    16 grid-institutes:grid.424469.9
    17 grid-institutes:grid.462854.9
    18 grid-institutes:grid.50550.35
    19 grid-institutes:grid.508487.6
    20 grid-institutes:grid.7429.8
    21 grid-institutes:grid.9621.c
    22 schema:familyName Tod
    23 schema:givenName Michel M
    24 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763711421.46
    25 schema:sdDatePublished 2022-12-01T07:12
    26 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    27 schema:sdPublisher N88f47c1aede548c6ae95b2bd87edd490
    28 sgo:license sg:explorer/license/
    29 sgo:sdDataset persons
    30 rdf:type schema:Person
    31 N88f47c1aede548c6ae95b2bd87edd490 schema:name Springer Nature - SN SciGraph project
    32 rdf:type schema:Organization
    33 N9bad6795a44d4d8faff52f902fe94e09 schema:affiliation grid-institutes:grid.7849.2
    34 sgo:isCurrent true
    35 rdf:type schema:OrganizationRole
    36 grid-institutes:grid.11318.3a schema:Organization
    37 grid-institutes:grid.25697.3f schema:Organization
    38 grid-institutes:grid.411119.d schema:Organization
    39 grid-institutes:grid.411388.7 schema:Organization
    40 grid-institutes:grid.411430.3 schema:Organization
    41 grid-institutes:grid.411784.f schema:Organization
    42 grid-institutes:grid.412134.1 schema:Organization
    43 grid-institutes:grid.413306.3 schema:Organization
    44 grid-institutes:grid.413780.9 schema:Organization
    45 grid-institutes:grid.413784.d schema:Organization
    46 grid-institutes:grid.413852.9 schema:Organization
    47 grid-institutes:grid.414106.6 schema:Organization
    48 grid-institutes:grid.417713.7 schema:Organization
    49 grid-institutes:grid.418116.b schema:Organization
    50 grid-institutes:grid.424469.9 schema:Organization
    51 grid-institutes:grid.462854.9 schema:Organization
    52 grid-institutes:grid.50550.35 schema:Organization
    53 grid-institutes:grid.508487.6 schema:Organization
    54 grid-institutes:grid.7429.8 schema:Organization
    55 grid-institutes:grid.7849.2 schema:Organization
    56 grid-institutes:grid.9621.c schema:Organization

    Preview window. Press ESC to close (or click here)